Poor Increase in Pulse Pressure during Cardiopulmonary Exercise Testing Predicts Prognosis in Patients with Heart Failure with Reduced Ejection Fraction

Poor Increase in Pulse Pressure during Cardiopulmonary Exercise Testing Predicts Prognosis in Patients with Heart Failure with Reduced Ejection Fraction - Relationship between poor pulse pressure increase during exercise and prognosis in HFrEF patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039250

Enrollment

224

Registered

2020-01-24

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HFrEF

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Data of patients who underwent symptom-limited maximal CPX between 2012 and 2016 were analyzed. The inclusion criteria were previous or present heart failure symptoms (New York Heart Association (NYHA) functional classes II-III, American College of Cardiology/American Heart Association (ACC/AHA) classification stage C), previous documentation of left ventricular systolic dysfunction (left ventricular EF (LVEF) <40%), stable clinical condition with unchanged medications for at least 3 months, ability to perform CPX, and no major cardiovascular treatments or interventions scheduled.

Exclusion criteria

Exclusion criteria: The exclusion criteria included a history of pulmonary embolism, moderate-to-severe aortic or mitral stenosis, pericardial disease, severe obstructive lung disease, exercise-induced angina and significant electrocardiographic alterations, or the presence of any clinical comorbidity that could interfere with exercising. Based on these criteria, 224 patients with HFrEF were enrolled.

Design outcomes

Primary

Measure	Time frame
A total of 224 patients with HFrEF who underwent symptom-limited maximal CPX between 2012 and 2016 were enrolled.The endpoint was cardiovascular death. Cardiovascular death was defined as any fatal event related to coronary heart disease, cerebrovascular disease, and other heart or vascular diseases, specifically fatal myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, heart failure, and arrhythmia.The time interval from the date of CPX to cardiovascular death was defined as the duration of follow-up. Endpoints were censored in October 2018.	—

Measure

Time frame

A total of 224 patients with HFrEF who underwent symptom-limited maximal CPX between 2012 and 2016 were enrolled.The endpoint was cardiovascular death. Cardiovascular death was defined as any fatal event related to coronary heart disease, cerebrovascular disease, and other heart or vascular diseases, specifically fatal myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, heart failure, and arrhythmia.The time interval from the date of CPX to cardiovascular death was defined as the duration of follow-up. Endpoints were censored in October 2018.

—

Countries

Japan

Contacts

Public ContactTaisuke Nakade

Gunma Prefectural Cardiovascular Center Department of Cardiology

t.nakade.gcvc@gmail.com027-269-7455

Outcome results